Sim SY, Ghulakhszian A, Minocha A, et al. - In this retrospective, real-world, multi-centre cohort study involving 221 patients (270 eyes), researchers sought to identify ocular and systemic characteristics that correlate with anatomical and functional outcomes for treatment-naive diabetic macular oedema (DMO) patients treated with intravitreal aflibercept. This investigation was carried out at three North West London Hospitals between January 2016 and July 2018 with data analysed between June 2020 and July 2020. The study is the largest real-world dataset in the UK examining factors influencing functional and anatomical response to aflibercept in DMO. Poorer visual acuity at 12 months was associated with older age, lower baseline best-corrected visual acuity, higher baseline central macular thickness, and more severe diabetic retinopathy, and these patients should be prioritised in a pressured healthcare setting.